HUTCHMED (China) Limited (HCM) RNS Announcements

Add to Alert list
Date Time Source Announcement
02 Feb 2024 08:37 AM
RNS
Inmagene Exercises Option for Two Drug Candidates
01 Feb 2024 08:30 AM
RNS
HUTCHMED to Announce 2023 Final Results
30 Jan 2024 07:12 AM
RNS
HUTCHMED Receives Marketing Approval in Hong Kong
11 Jan 2024 07:00 AM
RNS
Sovleplenib NDA Granted Priority Review in China
29 Dec 2023 08:30 AM
RNS
Total Voting Rights
29 Dec 2023 08:30 AM
RNS
Blocklisting Six Monthly Return
21 Dec 2023 10:00 AM
RNS
Overseas Regulatory Announcement
13 Dec 2023 07:00 AM
RNS
Inclusion in National Reimbursement Drug List
13 Dec 2023 07:00 AM
RNS
Completed Enrollment of Phase II/III Trial
07 Dec 2023 10:04 AM
RNS
Overseas Regulatory Announcement
01 Dec 2023 07:00 AM
RNS
Clinical Data to be Presented at Congresses
30 Nov 2023 08:30 AM
RNS
Total Voting Rights
09 Nov 2023 07:00 AM
RNS
U.S. FDA Approval of FRUZAQLA™ (fruquintinib)
24 Oct 2023 09:30 AM
RNS
Vesting of awards under the LTIP
16 Oct 2023 09:30 AM
RNS
Clinical Data to be Presented at ESMO 2023
29 Sep 2023 09:30 AM
RNS
Total Voting Rights
29 Sep 2023 09:30 AM
RNS
NDA Submission for Fruquintinib in Japan
14 Sep 2023 09:30 AM
RNS
Director’s Share Dealing
14 Sep 2023 09:30 AM
RNS
Director’s Share Dealing
12 Sep 2023 09:30 AM
RNS
Phase IIIb Savolitinib Results at WCLC 2023
12 Sep 2023 07:00 AM
RNS
Patient Enrollment Completed for Bridging Study
31 Aug 2023 09:30 AM
RNS
Total Voting Rights
29 Aug 2023 07:00 AM
RNS
BTD in China for Savolitinib for Gastric Cancer
21 Aug 2023 07:00 AM
RNS
Sovleplenib Phase 3 Study Meets Primary Endpoint
07 Aug 2023 09:30 AM
RNS
Exercise of Share Options by a Director
31 Jul 2023 12:00 PM
RNS
Interim Results and Business Updates
20 Jul 2023 07:00 AM
RNS
Breakthrough Therapy Designation for Fruquintinib
13 Jul 2023 09:30 AM
RNS
Changes to Board and Technical Committee
10 Jul 2023 07:00 AM
RNS
Phase 1 Study of HMPL-415 Initiated
29 Jun 2023 09:30 AM
RNS
Blocklisting Six Monthly Return
26 Jun 2023 09:30 AM
RNS
HUTCHMED to Announce 2023 Half-Year Results
16 Jun 2023 07:00 AM
RNS
Phase III FRESCO-2 Results in The Lancet
15 Jun 2023 03:39 PM
RNS
MAA of Fruquintinib Validated by the EMA
09 Jun 2023 10:30 AM
RNS
HUTCHMED Highlights Presentations at EHA and ICML
06 Jun 2023 10:00 AM
RNS
LTIP and Share Option Scheme
31 May 2023 09:30 AM
RNS
Total Voting Rights
26 May 2023 07:00 AM
RNS
HUTCHMED Highlights Presentations at ASCO 2023
26 May 2023 07:00 AM
RNS
Fruquintinib NDA Granted Priority Review by FDA
17 May 2023 09:30 AM
RNS
Standard form for notification of major holdings
12 May 2023 01:15 PM
RNS
Annual General Meeting Poll Results
12 May 2023 09:30 AM
RNS
Board of Directors and Board Committee Membership
10 May 2023 09:30 AM
RNS
Appointment of Independent NED
28 Apr 2023 09:30 AM
RNS
Total Voting Rights
21 Apr 2023 09:30 AM
RNS
Vesting of awards under the LTIP
21 Apr 2023 09:30 AM
RNS
Vesting of awards under the LTIP
18 Apr 2023 07:00 AM
RNS
NDA Acceptance in China for Fruquintinib
12 Apr 2023 07:00 AM
RNS
Presentations at AACR Annual Meeting 2023
11 Apr 2023 09:30 AM
RNS
Intended Retirement of Independent NED
11 Apr 2023 09:30 AM
RNS
2022 Annual Report and Notice of AGM
04 Apr 2023 10:30 AM
RNS
HUTCHMED Initiates Registration Phase Enrollments

Hutchmed China  Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) is headquartered in Hong Kong and markets its products worldwide.

It was founded in 2000 and listed in London in 2018 under the ticker HCM. 

UK 100